Anti-BAFFR CAR T therapy(The General Hospital Of Tianjin Medical University)

N/A

Report date: 2025/06/19 20:00:08

Base Information

Drug NameAnti-BAFFR CAR T therapy(The General Hospital Of Tianjin Medical University)
Drug Alias NameBAFFR CART
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-cell activating factor receptor modulatorsT lymphocyte replacements
TargetsB-cell activating factor receptor
Therapy Area/IndicationsPolyradiculoneuropathy, Chronic Inflammatory DemyelinatingNeuromyelitis OpticaMyositis +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesThe General Hospital Of Tianjin Medical University
China Registration ClassN/A

Develop Information

Active CompaniesThe General Hospital Of Tianjin Medical University
Inactive CompaniesN/A
Active IndicationsPolyradiculoneuropathy, Chronic Inflammatory DemyelinatingNeuromyelitis OpticaMyositis +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A